Eran Ovadya brings nearly two decades of broad experience in corporate finance, accounting, M&A transactions, IPOs, and RTOs. Eran has a professional track record from first tier global corporations and significant expertise in public life-science and publicly-traded companies. Mr. Ovadya is a CFO of NurExone Biologic Inc. (TSXV:NRX), a pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. In the past, Mr. Ovadya provided outsourced CFO services to a variety of companies including Silenseed, VVT Medical, Procore, Forrest Innovations, Cannibble and others. Prior to that, Eran served for over a decade in a variety of finance roles for biotech companies including Gamida Cell, West pharma Israel, Omrix Biopharmaceuticals, a division of Ethicon Biosurgery, a Johnson & Johnson company, Macrocure, and Leap Therapeutics. Mr. Ovadya holds an MBA, specializing in financing, and a BA in accounting & economics from the Open University, Israel.

Alex Storcheus has worked in corporate finance at Foundation Markets Inc., a private merchant bank based in Toronto, since 2010, most recently in the position of Managing Director, Corporate Finance. In such role, he has been involved in various financial and strategic advisory activities in the small-cap space including M&A and going public transactions. Mr. Storcheus was a director of Capricorn Business Acquisitions Inc. (currently SATO Technologies Corp., TSXV: SATO) from March 21, 2017 to September 7, 2021 and has been President and Director of Cave Creek Copper Inc., a private copper exploration company focused on Arizona from February 14, 2023 that is currently being acquired by Intrepid Metals . From July 25, 2023, Mr. Storcheus has been CEO of Cachee Gold Mines Corp., a private critical metals and gold exploration company focused on properties in Ontario and Quebec. Mr. Storcheus is the CFO of Rigel Technologies Inc., an unlisted reporting issuer. Mr. Storcheus received a Bachelor of Business Administration degree from the Schulich School of Business at York University with concentration in finance in 2011 and is a CFA Charterholder.

Dr. Davidovich brings over 20 years of international experience in the pharmaceutical and biotech industries, coupled with a profound expertise in neuromanagement, which applies neuroscience principles to business leadership and marketing. As a seasoned executive coach, he has offered guidance in neuroleadership across Europe, Canada, and the USA, enhancing corporate strategies through psychological insights. His academic journey spans continents and disciplines, holding an MD specialized in Internal Medicine from the University of Buenos Aires, and an MBA from Business School Lausanne. He is also well-versed in clinical psychology and hypnotherapy. Notably, Dr. Davidovich has served as Vice-President at Optimum Talent in Canada, where he led the Neuromanagement Centre. He is recognized by the Institute of Coaching at McLean Hospital, a Harvard Medical School affiliate, as a world-leading thought leader in coaching. Dr. Davidovich also engages in shamanic and spiritual practices, leading shamanic circles in Argentina, Europe, and Canada, reflecting his dedication to holistic well-being.

Aurora Sosa, BSc, MA – Ms. Sosa holds a BSc in Biology and a MA in Holistic Health and Counseling Psychology. She retains over 30 years of pharmaceutical experience, having completed her early career as a bench scientist at Bayer Pharmaceuticals and further progressing to regulatory affairs. Ms. Sosa has over 20 years of international regulatory experience leading internal and external cross-functional team efforts within biopharmaceuticals organizations as a strategic leader and contributor. Her in-depth experience covers several therapeutic areas including neurology, neuroimmunology, neuroinflammatory disease, rare disease, and rare pediatric disease. At present she is an independent regulatory affairs consultant specializing in US FDA pathways. Ms. Sosa has previously held Director of Regulatory Affairs roles at various US pharmaceutical companies including Dow Pharmaceutical Sciences, Aradigm Corp, and Ardelyx Inc., and held the position of VP Regulatory Affairs at Premier Consulting.

Dr. Mara Bilibajkich received her medical degree from Queen’s University in Kingston, Ontario, where she also completed her medical residency has been a practicing family physician since 1995. A serial healthcare entrepreneur who founded multiple clinic operations, both multi-disciplinary and cannabis focused, has a strong focus on mental health and wellbeing. With over 1,000 articles on cannabis written, Dr. Bilibajkich is a highly recognized thought leader in the controlled substance space, supporting the advancement of new treatments that promise much greater efficacy than the status quo. She also owns RxLeaf, the largest online patient focused medical cannabis media site, with online ecommerce sales in the United States and Cannadish where patients learn to make their own products with guidance Currently Dr. Bilibajkich is enrolled in a Psychedelic Psychiatry Fellowship with Integrative Psychiatric Program (IPI) that is affiliated with MAPS (Multidisciplinary Association For Psychedelic Studies).

Mr. Gonzalez has over 20 years’ experience in audit & assurance in South America, included 5 years of public and private audit practice, financial analysis, and corporate development in Canada. He is bilingual in English and Spanish and has led many assurance & non-assurance engagements for companies in the energy, mining & natural resources, real estate, manufacturing, and consumer business sector. He is a Chartered Professional Accountant in Ontario and Venezuela and holds a bachelor degree with major in Accounting from the Santa Maria University.

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London. He currently leads as the Founding Chair of DrugScience.org.uk and also sits as the Chair of the Scientific Advisory Board for COMPASS Pathways, Chair of the Scientific Advisory Board for AWAKN Life Sciences, and Psyched Wellness Ltd.

Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology. He has past leadership roles as the Managing Partner at Biotech Pharmacy and the President of MedMen. Dr. Fu is now the co-founder and current CEO of premier cannabis cultivation and manufacturing company Green Therapeutics, as well as the interim CEO of Australis Capital Inc.

Dr. Wieman has 20+ years of psychiatric experience and is a leader in Indigenous health and medical education. She is also a recognized advocate for those who have experienced systemic racism and who have significant barriers accessing health services including Indigenous peoples, homeless populations, LGBTQ2S, and mental health and substance abuse patients. Dr. Wieman currently serves as the Acting Deputy Chief Medical Officer of the First Nations Health Authority and also as the President of the Indigenous Physicians Association of Canada.

Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking. Most recently, he has served as president of Metro Compactor Service Inc. and iSmart Technology Inc. His years of experience in several senior management roles, as well as his CPA, CA, and CFA designations, has led him to his current position as a director at a leading Canadian Intermodal transportation company, Seaport Intermodal.

Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy. With past senior leadership at a medical cannabis company and a well-known Canadian pension fund, he is well-versed in the North American cannabis landscape as well as the capital markets surrounding it.

Dr. Dyck is a renowned scientist and professor with 30+ years of experience studying heart disease and pathogenesis of heart defects. He is also highly experienced in the field of drug discovery and commercialization. Dr. Dyck currently leads as a Professor in the Dept. of Pediatrics at the University of Alberta and serves as a Canada Research Chair in Molecular Medicine, a Director at the Cardiovascular Research Centre, and a Co-chairman at the National Research Council at Diabetes Canada.

Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology. His most notable successes include lobbying the United States Pharmacopeia (USP) to include new techniques for Impurity Analysis, sales efforts to the US-DEA for controlled substances, and a partnership with Health Canada that resulted in a leading drug counterfeit detection technology. Most recently, he was the Regional CEO of USA and Canada at private global engineering solutions firm, Maccaferri Ltd.